Search

Your search keyword '"Rasia, Sarah"' showing total 39 results

Search Constraints

Start Over You searched for: Author "Rasia, Sarah" Remove constraint Author: "Rasia, Sarah"
39 results on '"Rasia, Sarah"'

Search Results

1. Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study

2. Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up

4. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

5. Cladribine vs other drugs in MS: Merging randomized trial with real-life data

6. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis

7. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy

8. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis

9. Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study

10. Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD

12. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

13. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

15. The CSF Profile Linked to Cortical Damage Predicts Multiple Sclerosis Activity

16. First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study

17. Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis

18. MSJ790390_supplementary_material – Supplemental material for Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study

19. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.

20. Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study

21. A Real-Life Study of Alemtuzumab: Impact of Previous Therapies and Washout Period on Disease Activity (P6.349)

22. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis

27. Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD

29. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis

30. Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with natalizumab: a multicenter, observational study

31. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

32. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

33. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

34. Cladribine vs other drugs in MS: Merging randomized trial with real-life data

35. Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study

36. Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study

37. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.

38. Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.

39. Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS.

Catalog

Books, media, physical & digital resources